Page 110 - 《中国药房》2025年23期

783-794. prevention of cardiovascular outcomes in patients with
[24] 邢鑫秒. SGLT2抑制剂和GLP-1受体激动剂治疗2型糖 type 2 diabetes：a network meta-analysis[J]. Cureus，2024，
尿病伴或不伴心血管疾病的疗效和安全性的网状Meta 16（9）：e69711.
分析[D]. 沈阳：中国医科大学，2024. [35] TIAN L，AI S N，ZHENG H J，et al. Cardiovascular and
[25] CHEN L，XUE Q X，YAN C Y，et al. Comparative safety renal outcomes with sodium glucose co-transporter 2 in‐
of different recommended doses of sodium-glucose co‐ hibitors in patients with type 2 diabetes mellitus：a system
transporter 2 inhibitors in patients with type 2 diabetes review and network meta-analysis[J]. Front Pharmacol，
mellitus：a systematic review and network meta-analysis 2022，13：986186.
of randomized clinical trials[J]. Front Endocrinol，2023， [36] DUAN X Y，LIU S Y，YIN D G. Comparative efficacy of
14：1256548. 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-
[26] WANG M R，ZHANG X X，NI T，et al. Comparison of like peptide 1 receptor agonists interventions on cardiore‐
new oral hypoglycemic agents on risk of urinary tract and nal outcomes in type 2 diabetes patients：a network meta-
genital infections in type 2 diabetes：a network meta- analysis based on cardiovascular or renal outcome trials
analysis[J]. Adv Ther，2021，38（6）：2840-2853. [J]. Medicine（Baltimore），2021，100（30）：e26431.
[27] ZHANG Y S，ZHENG Y D，YUAN Y，et al. Effects of [37] JIANG Y，YANG P P，FU L H，et al. Comparative cardio‐
anti-diabetic drugs on fracture risk：a systematic review vascular outcomes of SGLT2 inhibitors in type 2 diabetes
and network meta-analysis[J]. Front Endocrinol，2021，12： mellitus：a network meta-analysis of randomized con‐
735824. trolled trials[J]. Front Endocrinol，2022，13：802992.
[28] MEMON R A，AKBARIROMANI H，VOHRA R R，et al. [38] SADAGOBAN GOPAL K，JEMI RACHEL S，BHAGYA
Comparison of cardiovascular outcomes between dapa‐ P，et al. Cost-effectiveness analysis of dapagliflozin ver‐
gliflozin and empagliflozin in patients with type 2 diabe‐ sus canagliflozin in treatment of type 2 diabetes mellitus
tes：a meta-analysis[J]. Cureus，2022，14（7）：e27277. [J]. J Appl Pharm Sci，2022，12（3）：171-178.
[29] KANI R，WATANABE A，MIYAMOTO Y，et al. Com‐ [39] NESLUSAN C，TESCHEMAKER A，WILLIS M，et al.
parison of effectiveness among different sodium-glucose Cost-effectiveness analysis of canagliflozin 300 mg versus
cotransoporter-2 inhibitors according to underlying condi‐ dapagliflozin 10 mg added to metformin in patients with
tions：a network meta-analysis of randomized controlled type 2 diabetes in the United States[J]. Diabetes Ther，
trials[J]. J Am Heart Assoc，2024，13（3）：e031805. 2018，9（2）：565-581.
[30] TÄGER T，ATAR D，AGEWALL S，et al. Comparative ef‐ [40] National Institute for Health and Care Excellence（NICE）.
ficacy of sodium-glucose cotransporter-2 inhibitors Empagliflozin in combination therapy for treating type 2
（SGLT2i）for cardiovascular outcomes in type 2 diabetes： diabetes[EB/OL].（2015-03-25）[2025-10-15]. https：//www.
a systematic review and network meta-analysis of ran‐ nice.org.uk/guidance/ta336.
domised controlled trials[J]. Heart Fail Rev，2021，26（6）： [41] National Institute for Health and Care Excellence（NICE）.
1421-1435. Canagliflozin，dapagliflozin and empagliflozin as mono‐
[31] MA J H，LU J C，SHEN P L，et al. Comparative efficacy therapies for treating type 2 diabetes [EB/OL].（2016-03-
and safety of sodium-glucose cotransporter 2 inhibitors 23）[2025-10-15]. https：//www. nice. org. uk/guidance/
for renal outcomes in patients with type 2 diabetes mel- ta390.
litus：a systematic review and network meta-analysis[J]. [42] JOHNSTON R，UTHMAN O，CUMMINS E，et al. Cana‐
Ren Fail，2023，45（2）：2222847. gliflozin，dapagliflozin and empagliflozin monotherapy
[32] WEI X B，WEI W，DING L L，et al. Comparison of the ef‐ for treating type 2 diabetes：systematic review and eco‐
fects of 10 GLP-1 RA and SGLT2 inhibitor interventions nomic evaluation [J/OL]. Health Technol Assess，2017，21
on cardiovascular，mortality，and kidney outcomes in type （2）：1-218[2025-10-15]. https：//doi.org/10.3310/hta21020.
2 diabetes：a network meta-analysis of large randomized [43] AMANDA S，BUTCHER R. Sodium-glucose co-transporter
trials[J]. Prim Care Diabetes，2021，15（2）：208-211. 2 inhibitors for the treatment of type 2 diabetes：a review
[33] QIU M，DING L L，WEI X B，et al. Comparative efficacy of clinical effectiveness，cost-effectiveness，and guidelines
of glucagon-like peptide 1 receptor agonists and sodium [EB/OL].（2019-06-14）[2025-10-15]. https：//www. ncbi.
glucose cotransporter 2 inhibitors for prevention of major nlm.nih.gov/books/NBK545104/.
adverse cardiovascular events in type 2 diabetes：a net‐ [44] NEAL B，PERKOVIC V，MAHAFFEY K W，et al. Cana‐
work meta-analysis[J]. J Cardiovasc Pharmacol，2021，77 gliflozin and cardiovascular and renal events in type 2 dia‐
（1）：34-37. betes.[J]. N Engl J Med，2017，377（7）：644-657.
[34] SINHA T，GUL U，BABAR N N，et al. The comparison of （收稿日期：2025-06-24 修回日期：2025-11-17）
the effectiveness of dapagliflozin and empagliflozin in the （编辑：陈 宏）

· 2984 · China Pharmacy 2025 Vol. 36 No. 23 中国药房 2025年第36卷第23期